These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 18373337)
1. Isoxazolone based inhibitors of p38 MAP kinases. Laufer SA; Margutti S J Med Chem; 2008 Apr; 51(8):2580-4. PubMed ID: 18373337 [TBL] [Abstract][Full Text] [Related]
2. Substituted isoxazoles as potent inhibitors of p38 MAP kinase. Laufer SA; Margutti S; Fritz MD ChemMedChem; 2006 Feb; 1(2):197-207. PubMed ID: 16892352 [TBL] [Abstract][Full Text] [Related]
3. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors. Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954 [TBL] [Abstract][Full Text] [Related]
4. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. Laufer S; Lehmann F Bioorg Med Chem Lett; 2009 Mar; 19(5):1461-4. PubMed ID: 19195885 [TBL] [Abstract][Full Text] [Related]
5. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening. Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590 [TBL] [Abstract][Full Text] [Related]
6. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules. Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653 [TBL] [Abstract][Full Text] [Related]
7. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties. Karcher SC; Laufer SA J Med Chem; 2009 Mar; 52(6):1778-82. PubMed ID: 19253982 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517 [TBL] [Abstract][Full Text] [Related]
9. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226 [TBL] [Abstract][Full Text] [Related]
10. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. Liu W; Liang Q; Balzar S; Wenzel S; Gorska M; Alam R J Allergy Clin Immunol; 2008 Apr; 121(4):893-902.e2. PubMed ID: 18395552 [TBL] [Abstract][Full Text] [Related]
11. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase. Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605 [TBL] [Abstract][Full Text] [Related]
12. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR. Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461 [TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors. Laufer SA; Ahrens GM; Karcher SC; Hering JS; Niess R J Med Chem; 2006 Dec; 49(26):7912-5. PubMed ID: 17181176 [TBL] [Abstract][Full Text] [Related]
16. Practical synthesis of a p38 MAP kinase inhibitor. Achmatowicz M; Thiel OR; Wheeler P; Bernard C; Huang J; Larsen RD; Faul MM J Org Chem; 2009 Jan; 74(2):795-809. PubMed ID: 19086898 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Kim DK; Lim JH; Lee JA; Dewang PM Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921 [TBL] [Abstract][Full Text] [Related]
19. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles. Pierre Koch ; Christiane Bäuerlein ; Hartmut Jank ; Stefan Laufer J Med Chem; 2008 Sep; 51(18):5630-40. PubMed ID: 18763757 [TBL] [Abstract][Full Text] [Related]
20. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Moss N; Breitfelder S; Betageri R; Cirillo PF; Fadra T; Hickey ER; Kirrane T; Kroe RR; Madwed J; Nelson RM; Pargellis CA; Qian KC; Regan J; Swinamer A; Torcellini C Bioorg Med Chem Lett; 2007 Aug; 17(15):4242-7. PubMed ID: 17560108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]